In this retrospective study, we first evaluated the effectiveness of Chemo+ICI in comparison with platinum-based chemotherapy (with or without Bev) for patients with EGFR-mutated, EGFR-TKI-resistant NSCLC in the real-world clinical setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.